Guangdong Marubi Biotechnology Co Working Capital to Net Assets Ratio
Guangdong Marubi Biotechnology Co working capital to net assets ratio. Guangdong Marubi Biotechnology Co (603983) has a Working Capital to Net Assets ratio of 32.1% as of June 2026. Working capital of CN¥1.10 Billion (current assets of CN¥2.27 Billion minus current liabilities of CN¥1.17 Billion) is measured against net assets of CN¥3.44 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Guangdong Marubi Biotechnology Co (2011–2025)
Working capital to net assets ratio of Guangdong Marubi Biotechnology Co from 2011 to 2025. This chart shows how Guangdong Marubi Biotechnology Co's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 32.1%, reflecting working capital of CN¥1.10 Billion against net assets of CN¥3.44 Billion CNY. See operational self-sufficiency of Guangdong Marubi Biotechnology Co to measure how many days the company can operate on defensive assets alone.
Guangdong Marubi Biotechnology Co Working Capital to Net Assets Ratio by Year (2011–2025)
Guangdong Marubi Biotechnology Co working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Guangdong Marubi Biotechnology Co from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 603983 asset base.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 30.6% | CN¥1.04 Billion | CN¥3.39 Billion | CN¥2.24 Billion | CN¥1.20 Billion | ▼ -8.8 pp |
| 2024 | 39.4% | CN¥1.36 Billion | CN¥3.45 Billion | CN¥2.95 Billion | CN¥1.60 Billion | ▼ -5.1 pp |
| 2023 | 44.5% | CN¥1.52 Billion | CN¥3.42 Billion | CN¥2.53 Billion | CN¥1.01 Billion | ▼ -3.8 pp |
| 2022 | 48.2% | CN¥1.57 Billion | CN¥3.25 Billion | CN¥2.24 Billion | CN¥668.47 Million | ▲ +3.9 pp |
| 2021 | 44.3% | CN¥1.40 Billion | CN¥3.16 Billion | CN¥1.98 Billion | CN¥576.55 Million | ▼ -18.9 pp |
| 2020 | 63.2% | CN¥1.90 Billion | CN¥3.00 Billion | CN¥2.68 Billion | CN¥786.64 Million | ▼ -26.3 pp |
| 2019 | 89.5% | CN¥2.39 Billion | CN¥2.67 Billion | CN¥3.13 Billion | CN¥740.04 Million | ▲ +11.2 pp |
| 2018 | 78.2% | CN¥1.08 Billion | CN¥1.38 Billion | CN¥1.79 Billion | CN¥709.39 Million | ▲ +7.3 pp |
| 2017 | 71.0% | CN¥681.31 Million | CN¥959.96 Million | CN¥1.30 Billion | CN¥619.49 Million | ▲ +9.3 pp |
| 2016 | 61.6% | CN¥510.42 Million | CN¥828.09 Million | CN¥1.15 Billion | CN¥634.71 Million | ▲ +10.4 pp |
| 2015 | 51.3% | CN¥367.14 Million | CN¥715.92 Million | CN¥1.02 Billion | CN¥649.88 Million | ▲ +9.9 pp |
| 2014 | 41.4% | CN¥250.44 Million | CN¥604.48 Million | CN¥847.93 Million | CN¥597.49 Million | ▲ +5.4 pp |
| 2013 | 36.1% | CN¥163.46 Million | CN¥453.11 Million | CN¥649.60 Million | CN¥486.14 Million | ▲ +30.1 pp |
| 2012 | 5.9% | CN¥13.97 Million | CN¥234.87 Million | CN¥483.79 Million | CN¥469.82 Million | ▲ +9.7 pp |
| 2011 | -3.7% | CN¥-5.48 Million | CN¥148.02 Million | CN¥443.46 Million | CN¥448.94 Million | — |